Member Info for DShox

Same as yesterday

...MMs refuse to raise price. Worthy of reporting to regulators, which I'll do shortly.

£6.5m cap - no stock left and MMs in last chance saloon. Major international medical co poised to buy one of IQ-AIs two operating businesses for cash + royalties. Once that's done, IB Neuro supercharges.

Joke MMs

Waiting for next MM giveaway...buy button ready :)

When MMs finish step dropping, load up. They will break at some point - maybe in the next 30 mins.

Sale or partnership process basically kicked off when Stone Checker got US FDA approval in Sept, addition to European CE mark and now Korean FDA approval. US FDA, like Korea, should lead to China quite quickly.

On 19 June, which was a major day for IB Neuro (other main subsidiary) being recognised as the National Standard for use in high grade brain tumors, Trevor stated the process of finding a buyer had recommenced with 2 parties.

Now on 05 August, an LOI signed with "a major international group wishing to buy Stonechecker for cash and royalties". My view, this a major equipment manufacturer that wants to integrate the software.

In the US alone, 600k ppl get kidney stones per year. Shockwave therapy kit costs $1m and each round of treatment $13k, which fail 29%, amounting to $2.3bn. The software is also now being sold across Europe and Korea.

When US FDA was granted, David Smith identified one Chicago clinic that treated 208 patients in one year with shockwaves, so mooted a $120k pa per clinic subscription model.

IQ-AI has nil debt, ended 2019 with c.£870k cash, raised another £90k in Jan and signed a new deal with AI Metrics as contract manufacturer.

In June, IB was awarded a$2.57m 5-yr grant so it's got plenty of funding for IB.

It is also developing IB Strokes leveraging the existing technology, which has COVID application. Even younger groups that show no meaningful respiratory symptoms are suffering strokes as a result of COVID.

Chief Exec owns 30% of IQ-AI and another director over 6%. Paultry market cap of £7m. No idea how MMs could walk it down, but they did. It's cheap, very cheap.

Lets see how many times we hit NT again.

Market cap is £7m and the directors own 36%.

My guess, it's a major equipment manufacturer that wants to integrate StoneChecker into its scanning equipment.

...reported. Spread was played today and NT to buy at several points, yet the SP ended "only" 44% up. Something fishy going on in Mr Market.

Except here Steve, a major pharma has signed an LOI and the co is confident enough to say its "cash and royalties". Market inefficiency allows purchases now at this market cap, but cash will rotate into this stock and the sells will exhaust. Now's the time.

Bit like saying why would EUAs share price be 0.6p before it announced sale process and now sits at 17.5p with a good chance of going over £1.

My advice, raise your game.

...who always seems to buy the instant the Ask ticks up. MMs can buy before you in a rising market and sell before you in a falling market.

MMs fundamentally failing to maintain an orderly market. Cant even buy £500.

Jokes

Say no more

Cash at year end was £866k. Post period end it raised another £100k. Its annual pre-covid burn was £860k. And "during the year, the Group did not invest in any capital expenditure (2018: £nil). The Group made an investment in product development during the period of £112,115".

I see very limited risk of dilution pre potential transformational deal and re-rate. Punters should note it's not all about StoneChecker either.

Volume backed boom. If I wanted a spike I'd be trawling the top risers.

I should have said NT to buy £1k at 5.6p...Ask then shifted up to 5.8p. But shows its tight and you can't trust the spread or L2 to gauge stock availability. My view, some PR to clarify size puts this firmly on a run.

Phew thanks - that could've gone either way. I'm good at making lots of friends on LSE you see :)